Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
07:00am, Wednesday, 09'th Apr 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
10:10am, Monday, 31'st Mar 2025
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
06:58am, Thursday, 13'th Mar 2025
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
10:46am, Friday, 28'th Feb 2025
Glaukos Corporation GKOS reported record fourth-quarter 2024 revenues of $105.5 million, reflecting a 28% year-over-year increase. This growth was driven by strong demand for its innovative glaucoma a
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
09:12am, Monday, 24'th Feb 2025
On Monday, Glaukos Corporation GKOS received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epiox
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
07:00am, Monday, 24'th Feb 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
09:40am, Friday, 21'st Feb 2025
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript
04:29am, Friday, 21'st Feb 2025
Glaukos Corporation (NYSE:GKOS ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President, Investor Relations and Corporate Affairs Tom Burns - C
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
06:40pm, Thursday, 20'th Feb 2025
Glaukos (GKOS) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.63 per share a year ago.
What to Expect From These 3 MedTech Stocks This Earnings Season?
08:21am, Wednesday, 19'th Feb 2025
Here is a sneak peek into how three MedTech stocks, GKOS, ITGR and AMN, are expected to fare in their quarterly results, slated to be released tomorrow.
What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings
10:21am, Monday, 17'th Feb 2025
Beyond analysts' top -and-bottom-line estimates for Glaukos (GKOS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
02:46pm, Friday, 07'th Feb 2025
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
07:00am, Thursday, 23'rd Jan 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
GKOS Stock Gains Following Positive Study Data on iDose Platform
09:55am, Wednesday, 15'th Jan 2025
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
04:05pm, Tuesday, 14'th Jan 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
